Arcturus Therapeutics Holdings Inc. faces a solid cash runway into 2028, pipeline setbacks, and risk/reward profile. Learn ...
XPPen Artist 12 Gen3 addresses the category’s core pain point - "professional devices can’t be portable, while portable devices are not Pro enough". The overall performance surpasses that of most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback